DelveInsight has launched a new report on “Hyperkalemia – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Hyperkalemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Hyperkalemia Market Report:
In 2020, the diagnosed prevalent population of Hyperkalemia in Japan was found to be 503,103, which might increase during the study period of 2018–2030.
As per the analysis, males contributed to 55% of the total Hyperkalemia patient population in Japan in 2020. As per DelveInsight’s analysis, in Japan, there were 276,707 males and 226,397 females with hyperkalemia in 2020.
In Japan, the maximum number of Hyperkalemia patients fall in the age group of 65–79 years, which will contribute 41.66% in 2020. The lowest proportion of the population was contributed by the age group of 18–64 years.
As per DelveInsight’s analysis, mild cases contributed to 72.5% of the total population in 2020 as compared to moderate and severe cases. While moderate and severe cases only contributed to 19.6% and 7.8%, respectively.
Key benefits of the report:
The hyperkalemia market report covers a descriptive overview and comprehensive insight of the Hyperkalemia Epidemiology and Hyperkalemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Hyperkalemia market report provides insights into the current and emerging therapies.
Hyperkalemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Hyperkalemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hyperkalemia market.
Hyperkalemia is defined as the high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.
The dynamics of the Hyperkalemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Ardelyx, AstraZeneca, Vifor Pharma, and others during the forecasted period 2018-2030.
Hyperkalemia Pipeline Therapies and Key Companies
Veltassa: Vifor Pharma
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hyperkalemia Patient Share (%) Overview at a Glance
5. Hyperkalemia Market Overview at a Glance
6. Hyperkalemia Disease Background and Overview
7. Hyperkalemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperkalemia
9. Hyperkalemia Current Treatment and Medical Practices
10. Unmet Needs
11. Hyperkalemia Emerging Therapies
12. Hyperkalemia Market Outlook
13. Country-Wise Hyperkalemia Market Analysis (2018-2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Hyperkalemia Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Hyperkalemia Market Outlook 2030.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States